Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 453-457

  Lin, Ko Chung ^a   Castro, Alfredo C ^b  

^a BIOGEN   (United States)

^b ProScript   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMING RECEPTOR; INTEGRIN; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; VERY LATE ACTIVATION ANTIGEN 4;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CLINICAL TRIAL; CYCLIZATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; HUMAN; MOLECULAR GENETICS; MOLECULAR MIMICRY; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CYCLIZATION; DRUG DESIGN; DRUG EVALUATION; HUMANS; INTEGRIN ALPHA4BETA1; INTEGRINS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; PEPTIDES; RECEPTORS, LYMPHOCYTE HOMING;

EID: 0032135083     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80120-8     Document Type: Article

References (22)

1. Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
2. Lobb RR, Hemler ME: The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994, 94:1722-1728.
3. Morimoto C, Iwata S, Tachibana K: VLA-4-mediated signaling. Curr Top Microbiol Immunol 1998, 231:1-22.
4. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG: Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 1989, 109:1321-1330.
5. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990, 60:577-584.
6. 1. Cell 1990, 60:53-61.
7. 1 integrin. Nature 1992, 63:356.
8. Chisholm PL, Williams CA, Lobb RR: Monoclonal antibodies to the integrin α-4 subunit inhibit the murine contact hypersensitivity response. Eur J Immunol 1993, 23:682-688.
9. 4 integrin monoclonal antibody. J Clin Invest 1993, 92: 372-380.
10. Abraham WM, Sielczak MW, Ahmed A, Cortes A, Lauredo IT, Kim J, Pepinsky B, Benjamin CD, Leone DR, Lobb RR et al.: Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest 1994, 93:776-787.
11. Lobb RR, Pepinsky B, Leone DR, Abraham WM: The role of alpha 4 integrins in lung pathophysiology. Eur Respir J 1996, 9(suppl):104-108.
12. Nakamura S, Ohtani H, Watanabe Y, Fukushima K, Matsumoto T, Kitano A, Kobayashi K, Nagura H: In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993, 69:77-85.
13. Wayner EA, Kovach NL: Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin. J Cell Biol 1992, 16:489-497.
14. 1 (VLA-4, CD49d/CD29). Biochem J 1995, 305:945-951.
15. Bochner BS, Luscinskas FW, Gimbrone MA Jr, Newman W, Sterbinsky SA, Derse-Anthony CP, Klunk D, Schleimer RP: Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991, 173:1553-1557
16. Vanderslice P, Ren K, Revelle JK, Kim DC, Scott D, Bjercke RJ, Yeh ET, Beck PJ, Kogan TP: A cyclic hexapeptide is a potent antagonist of alpha 4 integrins. J Immunol 1997, 158:1710. This describes the design and discovery of a potent cyclic peptide VLA4 antagonist.
17. Tamraz S, Arrhenius T, Chiem A, Forrest MJ, Gaeta FC, He YB, Lei J, Maewal A, Phillips ML, Vollger LW et al.: Treatment of delayedtype hypersensitivity with inhibitors of the VLA-4 integrin. Springer Semin Immunopathol 1995, 16:437-441.
18. Abraham WM, Ahmed A, Sielczak MW, Narita M, Arrhenius TS, Elices MJ: Blockade of late-phase airway responses and airway hyperresponsiveness in allergic sheep with a small-molecule peptide inhibitor of VLA-4. Am J Respir Crit Care Med 1997, 156:696-703. This paper describes the design of effective small-molecule VLA4 antagonists.
19. 1 integrin-mediated cell adhesion. J Biol Chem 1993, 268:20352-20359.
20. 1 interaction with connecting segment 1 and vascular cell adhesion molecule. J Biol Chem 1994, 269:18668-18673.
21. 1 peptide antagonists as potential anti-inflammatory agents. J Med Chem 1997, 40:3359-3368. This paper describes the discovery of a cyclic VLA4 antagonist peptides that function in the nanomolar range.
22. Greenspoon N, Hershkoviz R, Alon R, Gershonov E, Lavie B, Lider O: Novel -ψ-S-CH2 peptide-bond replacement and its utilization in the synthesis of nonpeptidic surrogates of the Leu-Asp-Val sequence that exhibit specific inhibitory activities on CD4+ T cell binding to fibrinectin. Int J Peptide Protein Res 1994, 43:417-434.